GlassScriptPhysician profile
Donald Anthony Spisak
NPI 1699737056
$7,963.05
in general payments reported to CMS, 2019-2025
39 companies · $1,930 in 2025
The $1,930 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $679 · 2021: $891 · 2022: $998 · 2023: $1,333 · 2024: $1,924 · 2025: $1,930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,097 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,097.04 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,501.57 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $1,473.13 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Pfizer INC. | $674.65 | 2021-2025 | |
| Lilly USA, LLC | $669.08 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $606.96 | 2019-2024 | Jardiance, Tradjenta, Synjardy |
| Astellas Pharma US INC | $380.30 | 2021-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $292.45 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $247.25 | 2021-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Janssen Pharmaceuticals, INC | $212.99 | 2020-2025 | Xarelto, Spravato |
| Abbott Laboratories | $177.03 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $169.43 | 2023-2025 | Rexulti |
| Alkermes, INC. | $148.65 | 2022-2024 | Vivitrol, Vivitrol |
| Exact Sciences Corporation | $129.31 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $121.00 | 2021-2025 | Repatha, Otezla, Otezla |
| Phathom Pharmaceuticals, INC. | $112.78 | 2024-2025 | Voquezna |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Spisak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.